Zealand Pharma’s petrelintide cuts up to 9.2% body weight in Phase II ZUPREME-2

The notable signal is not the weight-loss figure alone but the pairing of meaningful glycemic improvement with placebo-level gastrointestinal discontinuation, the tolerability hurdle that has constrained this drug class. Demonstrating both in a type 2 diabetes population — a group that often responds less well to incretin-based approaches — broadens the potential addressable cohort beyond the overweight/obese label ZUPREME-1 addressed. The open question is whether the safety profile and effect size hold in larger, longer trials, and how regulators weigh a mid-single-digit HbA1c effect in a crowded field.